Furthermore, in phase 2 and 3 clinical trials in DMD young patients, NF-κB inhibitors such as flavocoxid or edasalonexent, showed to reduce the serum levels of IL-1β and TNF-α, slowed-down the disease progression and preserved muscle function [78,79,80], indicating that NF-κB might be a promising targeted therapy for MDs. This evidence concerns the gene IL1B and Duchenne muscular dystrophy.